Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan

BACKGROUND: This study evaluated safety, reactogenicity, and immunogenicity of a 2-month homologous booster regimen of Ad26.COV2.S in Japanese adults. METHODS: In this multicenter, placebo-controlled, Phase 1 trial, adults (Cohort 1, aged 20–55 years, N = 125; Cohort 2, aged ≥ 65 years, N = 125) wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchiya, Yumi, Tamura, Hiroshi, Fujii, Koji, Numaguchi, Hirotaka, Toyoizumi, Kiichiro, Liu, Tina, Le Gars, Mathieu, Cárdenas, Vicky, Eto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812825/
https://www.ncbi.nlm.nih.gov/pubmed/36732164
http://dx.doi.org/10.1016/j.vaccine.2023.01.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812825/
https://www.ncbi.nlm.nih.gov/pubmed/36732164
http://dx.doi.org/10.1016/j.vaccine.2023.01.006

Ejemplares similares